<DOC>
	<DOCNO>NCT00982930</DOCNO>
	<brief_summary>This open-label , single arm ( uncontrolled ) study subject suffer cystic fibrosis , complete study participation CTBM100C2303 ( visit ) proven infect Pseudomonas aeruginosa enrollment CTBM100C2303 .</brief_summary>
	<brief_title>Open Label Extension Bridging Study CTBM100C2303</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Completed visit study CTBM100C2303 , visit 4 take place 5 day enrollment study . Confirmed diagnosis cystic fibrosis patient P. aeruginosa infection . FEV1 screening ( study CTBM100C2303 ) must 25 % 80 % normal predict value . Any use inhale antipseudomonal antibiotic termination core trial CTMB100C2303 enrollment study . Known local systemic hypersensitivity aminoglycosides inhale antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tobramycin Inhalation Powder</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
</DOC>